Table 1.
Twenty-four best compounds with averaged normalized relative luciferase activity ≥1.20 and CV% <0.20 (n = 4)
| Compounds | Mean | SD |
|---|---|---|
| Tomatine | 1.50 | 0.16 |
| Tannic acid | 1.47 | 0.20 |
| Troxerutin | 1.44 | 0.22 |
| Camptothecin | 1.43 | 0.12 |
| Mexiletine hydrochloride | 1.43 | 0.21 |
| Halcinonide | 1.42 | 0.07 |
| Clobetasol propionate | 1.40 | 0.21 |
| 6α-Methylprednisolone acetate | 1.40 | 0.27 |
| Flurandrenolide | 1.33 | 0.19 |
| Oxethazaine | 1.31 | 0.11 |
| Ketorolac tromethamine | 1.28 | 0.09 |
| Avocadynone acetate | 1.27 | 0.10 |
| Medrysone | 1.26 | 0.19 |
| Propafenone hydrochloride | 1.26 | 0.10 |
| Etodolac | 1.24 | 0.11 |
| Propylthiouracil | 1.23 | 0.06 |
| Pergolide mesylate | 1.23 | 0.03 |
| Hydrocortisone butyrate | 1.22 | 0.10 |
| 5-Azacytidine | 1.22 | 0.05 |
| Alexidine hydrochloride | 1.22 | 0.10 |
| Fluconazole | 1.21 | 0.10 |
| Methoxyamine hydrochloride | 1.21 | 0.09 |
| N-Formylmethionylalanine | 1.21 | 0.11 |
| Dinitolmide | 1.20 | 0.08 |
Among the 80 compounds that we employed for the second round of screening, 24 compounds consistently demonstrated beneficial responses. The values are the global mean and SD of the first (n = 2) and second (n = 2) rounds of screening.